ACTM-838, a microbial-based immunotherapy that enriches in solid tumors after IV dosing, reverses the immunosuppressive TME to promote durable anti-tumor immunity, alone and in combination with anti-PD1 in mice

ACTM-838 - Actym Therap

https://jitc.bmj.com/content/10/Suppl_2/A1105

Akshata Udyavar; Hailey He; John Brandenburg; Julie Janes; Oanh Pham; Sara Tribble; Ryan Daroy; Keith Cheung; Haixing Kehoe; Bret Peterson; Emily Miyashita-Lin; Omkar Joshi; Nick Eisele; Christopher Thanos; Chan Whiting

Oct 6, 2022